(MedPage Today) — The FDA has approved the first implantable device to treat advanced retinitis pigmentosa, the agency announced.
FDA Approves Retinal Prosthesis, a ‘Bionic Eye’
The FDA has approved the Argus II Retinal Prosthesis System, the first ‘bionic eye,’ allowing US implants to begin in people blinded by retinitis pigmentosa. FDA Approvals
Uncategorized
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein
Source: Cochrane
Area: Evidence > Drug Class Focused Reviews
Background
Branch retinal vein occlusion (BRVO) is one of the most common occurring retinal vascular abnormalities. The pathogenesis of BRVO is thought to involve both retinal vein compression and damage to the vessel wall, possibly leading to thrombus formation at sites where retinal arterioles cross retinal veins. The most common cause of visual loss in patients with BRVO is macular oedema (MO). Grid or focal laser photocoagulation has been shown to reduce the risk of visual loss and improve visual acuity (Read more...)
Does Aspirin Cause Macular Degeneration?
Australian researchers claim aspirin use may cause macular degeneration. Many take aspirin to prevent heart attacks. What can you do?
Uncategorized
FDA approves Argus II Retinal Prosthesis System
The Argus II Retinal Prosthesis System from Second Sight Medical Products has been approved by the U.S. Food and Drug Administration.The system, designed to treat adults with advanced retinitis pigmentosa, includes an external small video camera, video processing unit and transmitter fixed to eyeglasses, along with electrodes implanted internally onto the patient’s retina, according to an FDA press release.
Amblyopia screening guidelines updated
The American Association for Pediatric Ophthalmology and Strabismus, the professional body for pediatric eye care, has issued revised guidelines for preschool vision screening based on new evidence.